Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05036005
Title Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON) (NeoON)
Recruitment Recruiting
Gender female
Phase FDA approved
Variant Requirements No
Sponsors Institut fuer Frauengesundheit
Indications

Her2-receptor positive breast cancer

Therapies

Pertuzumab + Trastuzumab

Trastuzumab

Age Groups: senior | adult
Covered Countries DEU


No variant requirements are available.